Neoadjuvant Nivolumab Checks Lung Cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2018-049
Abstract: The PD-1 inhibitor nivolumab given prior to surgical removal of early-stage non-small cell lung cancer is safe and produces a high rate of pathologic response, especially among those with high tumor mutation burden. read more here.
Keywords: checks lung; nivolumab checks; neoadjuvant nivolumab; lung cancer ... See more keywords